ES
MARKETS / NASDAQ / NVNO
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

enVVeno Medical Corporation NVNO

9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-33.06
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-56.2%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 9-year series below
Revenue Net income
0.00020.00040.0006-0.02017202020232025
0.00020.00040.0006-0.02017202020232025

Per share
USD -33.06
Diluted EPS, FY2025
EPS
0.40.81.2-33.062017202020232025
0.40.81.2-33.062017202020232025

The company pays no cash dividend.

Profitability
-56.2%
Return on equity, FY2025
ROE
0.250.50.751-56.2%2017202020232025
0.250.50.751-56.2%2017202020232025
Operating margin—
Net margin—
Return on assets-52.3%

Each USD of equity lost 56 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.010.002017202020232025
0.010.002017202020232025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 29.6M
total assets, end of FY2025
Total assetsUSD 29.6M
EquityUSD 27.1M
CashUSD 3.1M
Current ratio13.58×

Equity funds 92% of total assets.

History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
·
·
·
·
·
·
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−33.06
−44.53
−1.91
−2.20
−1.90
−7.54
−12.10
−1.75
−1.35
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−56.2
−49.4
−55.4
−53.0
−53.7
−225.9
−503.9
·
·
Shares out B
0.00
0.00
0.01
0.01
0.01
0.00
0.00
0.01
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed